The National Engineering Laboratory is one part of a systematic project to rejuvenate China through science and technology by implementing the "National Medium and Long Term Science and Technology Plan," the "Peoples Republic of China National Economy and Society Developed 11th Five Year Plan Summary" and the "11th Five-Year Plan for Construction Independent Innovation Ability." China is planning to set up 100 national engineering laboratories, only one laboratory in each specific scientific field nationwide, as technology innovation centers, breakthrough centers for technologies recognized globally as critical for the future, high technology talent centers, and centers for promoting the commercialization of scientific and technological achievements. In July 2008 at Chinas Second Bioindustry convention, Guanhao Biotech Co., Ltd. won from Chinas National Development and Reform Commission a prestigious award for its "National Engineering Laboratory for Regenerative Medical Implantable Devices." Guanhao received the highest award grade because of its" international advanced technology, powerful R&D capabilities, strong management team, excellent technology achievements, and innovative operational approach.
Guanhao has purchased more than 30,000 square meters in Guangzhou Science Park to construct the building that will house the National Engineering Laboratory. In addition to the technology and product departments composed of four research centers and four basic laboratories, the building will include a commercialization department to make practical use of the laboratory’s scientific and technological achievements, a department to promote technology exchange and cooperation globally, and a state-of-the-art technology platform to drive regenerative breakthroughs. A facility for properties testing and animal experiments as well as workspaces for participants in doctoral and postdoctoral programs to foster the development of regenerative medicine experts will also be built in the near future.
Guanhao’s “National Engineering Laboratory for Regenerative Medical Implantable Devices” will be develop as a technology innovation center, a high technology talent center, and a center for promoting the commercialization of scientific and technological , and it will definitely make significant contribution to the progress of the regenerative medicine industry in China.
Guanhao has the first GMP grade cell bank in China, covering an area of 420 square meters. It has set up independent route for people, logistics channels, cell storage areas and functional auxiliary areas to prevent contamination and crossed contamination to the greatest extent. It can accommodate 21 large liquid nitrogen tanks (1770L), and has a capacity to store 2 million cell samples.
To ensure the safety of stored samples to the greatest extent, Guanhao cell bank is equipped with automatic liquid nitrogen addition, remote temperature monitoring system and international branded sample information management system.
Guangdong Zhonghao Pharmaceutical Co., Ltd., a subsidiary of Guanhao, has a manufacturing plant that is GMP certified by Guangdong Provincial Drug Administration. It has more than 150 special-line manufacturing equipment and 58 high-end precision instruments. The plant is expected to produce 1,000 kg of API and 10 million tubes of Symbiox® per year, which could fulfill 1 million patient population.
Dr. Chen obtained his doctorate degree from Simon Fraser University, Canada. He is the person in charge of the major scientific and technological projects of the "12th Five-Year Plan" and "Major New Drug Creation". He is the inventor and PI for Symbiox®,. He was also an adjunt professor of South China University of Technology
He is a senior researcher at the University of South Florida and Moffitt Cancer Research Center, and he is the member of the American Pharmaceutical Association and the member of the American Biochemistry and Molecular Biology, he is on the Guangdong Science and Technology Project Scientific Committee.
Professor Deng obtained his doctorate degree in Immunology from University of California. He is theDirector of Stem Cell Research Center in Peking University, Distinguished Professor of Yangtze River, School of Life Sciences, Peking University, and Board Member of the International Stem Cell Society (ISSCR). It undertakes major scientific research projects such as the national “973” and the national “863”. He has published more than 100 papers in journals such as Nature, Cell, Science, and CellStem Cell. He applied for 5 international patents and won the Beijing Science and Technology Award. In 2013, he won the National Science and Technology Innovation Award and the 2014 Tanjiatun Life Science Achievement Award.
Professor Xu is one of the pioneers in China’s ’ Biomaterial Engineering field. He co-authored a book called“Biomedical Material Science”, which has been a major textbook for Chinese professionals studying in biomedical engineering. Professor Xu is the cofounder of the Biomaterial Committee of the Chinese Biomedical Engineering Society, where he served for 12 years as Chairman. He was also the founder and Vice Chancellor of Biomedical Engineering Research Institute of Jinan University.